CLAIMS

1. Use of a compound selected from the group consisting of triamterene and nolatrexed or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prevention of phenylketonuria.

2. The use according to claim 1, wherein the compound is triamterene or a pharmaceutically acceptable salt thereof.

3. The use according to claim 2, wherein the compound is triamterene.

4. The use according to claim 1, wherein the compound is nolatrexed or a pharmaceutically acceptable salt thereof.

5. The use according to claim 4, wherein the compound is nolatrexed dihydrochloride.

6. The use according to any one of the preceding claims, wherein the phenylketonuria is selected from variant phenylketonuria, non-phenylketonuria hyperphenylalaninemia and classic phenylketonuria.

7. The use according to claim 6, wherein the phenylketonuria is variant phenylketonuria.

8. Use of a combination comprising one or more compounds selected from the group consisting of triamterene, nolatrexed, sultopride, hydrastinine, bufuralol, valganciclovir, ricobendazole, albendazole, valacyclovir, minoxidil, loxoribine, sapropterin, sepiapterin, oxitriptan, pyrimethamine, pegvaliase, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prevention of phenylketonuria (PKU), wherein at least one compound is selected from the group consisting of triamterene and nolatrexed or a pharmaceutically acceptable salt thereof.

9. The use of the combination according to claim 8, wherein the combination comprises at least one compound as defined in any one of claims 2-5.

10. The use of the combination according to claim 8 or 9, wherein the phenylketonuria is selected from variant phenylketonuria, non-phenylketonuria hyperphenylalaninemia and classic phenylketonuria.

11. The use of the combination according to claim 10, wherein the phenylketonuria is variant phenylketonuria.